Home / Going-concern warnings / Verrica Pharmaceuticals Inc.
Filed 2026-03-11 路 Form 10-K 路 Accession 0001660334-26-000008 micro
Price before filing: $5.98 (2026-03-10 close, split/dividend-adjusted)
Market cap at flag: $66.7M (2026-03-11) 路 Latest: $76.7M (2026-10-16)
| Window | VRCA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -14.5% | +0.6% | -15.2% | 2026-04-10 |
| 90 days | +2.3% | +9.1% | -6.8% | 2026-06-09 |
| 180 days | -12.0% | +13.7% | -25.8% | 2026-09-08 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"As discussed in Note 1 to the financial statements, the Company has incurred substantial operating losses since inception and has negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: KPMG LLP
Source: independent auditor report in Form 10-K (period 2025-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.